GENEART Concludes Project to Complete the National Institutes of Health's Mammalian Gene Collection
News Nov 12, 2008
GENEART AG announces the successful conclusion of its project with the US National Cancer Institute in regard to the "Mammalian Gene Collection" (MGC).
Over the past two years GENEART has synthesized approximately 2,400 genes and 1,500 gene variants for the MGC's completion with an order volume of about USD 6M. These were in large parts highly complex gene sequences, which could not be isolated within the scope of the MGC project using classic methods of biotechnology over the years 2002 to 2006.
The MGC can now provide scientists worldwide with access to all 25,000 human genes. A progress, which may tremendously expedite the search for therapies and drugs.
"The MGC's completion is as similarly a historic event as the finalization of the Human Genome Project in 2004", stated Prof. Dr. Ralf Wagner CEO/CSO of GENEART AG. "We are therefore pleased that we were able to overcome the problems of traditional technologies with our gene synthesis platform and to directly contribute to this scientific accomplishment."
At the time it was achieved to completely decode the human genome within approximately 14 years, and thus to provide the order of the letters of the human gene sequence in electronic form for the first time. The MGC's completion now provides scientists with access to the respective physical genes.
"We anticipate the MGC gene library to contribute to a further opening of the market and to provide additional growth impulses for the gene synthesis market", stated Christian Ehl, CEO/CFO of GENEART AG. "Because quick access to the human genome opens diverse opportunities for biomedical applications and thus also promotes demand for customized genes for the development of innovative drugs and therapy concepts."
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE